This report was recently updated on April 23 2025 with the latest and most recent
market numbers
Global Sepsis Therapeutics Market Size, Trends & Analysis - Forecasts to 2030 By Drug Class (Cephalosporin, Aminoglycosides, Glycopeptide, and Others), By Route of Administration (Parenteral, Oral, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Asia Pacific, Central and South America, Europe, and Middle East and Africa), Competitive Landscape, Company Market Share Analysis, and End User Analysis
The global sepsis therapeutics market is estimated to exhibit a CAGR of 7.2% from 2025 to 2030.
The primary factors propelling the market growth are the rising global incidence of sepsis due to aging populations and chronic disease prevalence, and increasing awareness and early diagnosis initiatives by healthcare authorities. As the elderly are more susceptible to infections and have weakened immune responses, they are at a higher risk of developing sepsis, especially following surgeries or hospital admissions. Additionally, patients with chronic conditions such as diabetes, cancer, kidney disease, or respiratory disorders often experience compromised immunity and frequent hospitalizations, further increasing their vulnerability to sepsis. In both industrialized and emerging nations, where lifestyle-related illnesses are becoming more prevalent, this tendency is especially noticeable. Consequently, healthcare systems are witnessing a surge in sepsis cases, leading to increased demand for effective therapeutic interventions, including antibiotics, immunotherapies, and supportive care. This market driver is prompting pharmaceutical companies to invest in R&D for advanced treatments, while governments and health organizations are emphasizing early diagnosis and treatment protocols to reduce mortality.
Advancements in biomarker-based diagnostics, along with the growing demand for targeted and personalized sepsis treatments, are expected to support the market growth. Conventional diagnostic techniques frequently postpone the detection of sepsis, which, if left untreated, can cause serious consequences or even death. However, biomarker-based diagnostics—such as procalcitonin (PCT), C-reactive protein (CRP), and interleukins—allow clinicians to detect sepsis in its early stages by identifying specific biological indicators of infection and inflammation. These tools improve diagnostic accuracy, reduce reliance on empirical treatments, and support the timely initiation of targeted therapies. As a result, medical professionals can improve patient outcomes, decrease intensive care unit stays, and implement more efficient treatment regimens. Furthermore, these diagnostics' usefulness in clinical settings is being further increased by their integration with AI-driven platforms and point-of-care testing.
The rising hospital-acquired infections (HAIs) and antimicrobial resistance (AMR), coupled with the government and NGO funding for sepsis research and management, propel market growth. HAIs, often caused by prolonged hospital stays, surgical procedures, and invasive devices like catheters and ventilators, are a leading cause of sepsis in healthcare settings. As these infections become more frequent, especially in overcrowded or under-resourced hospitals, the risk of sepsis increases substantially. Compounding this issue is the surge in antimicrobial resistance, which limits the effectiveness of standard antibiotic treatments and complicates sepsis management. This has created an urgent need for novel and more potent therapeutic options, including broad-spectrum antibiotics, immunomodulators, and combination therapies. Research organizations and pharmaceutical corporations are currently making significant investments in creating next-generation therapies that can defeat infections with high resistance.
The opportunity to create tailored treatments that influence particular immune pathways and cytokine reactions in sepsis patients is increasing. These therapies offer personalized treatment approaches, which are increasingly in demand due to varied patient responses to conventional drugs. Additionally, the high vulnerability of neonates and children to sepsis presents an opportunity for companies to develop age-specific therapeutics. Innovations in pediatric formulations can address this unmet medical need and drive growth in this specialized segment of the market. However, the lengthy and complex regulatory process for new sepsis drugs and low awareness about sepsis symptoms impede market growth.
The cephalosporin segment is expected to hold the largest share of the market over the forecast period. Cephalosporins are generally well-tolerated with fewer severe side effects compared to other antibiotic classes, encouraging their use in both adult and pediatric sepsis patients. Their relatively safe profile contributes to high prescription rates in critical care settings.
The glycopeptide segment is expected to be the fastest-growing segment in the market from 2025 to 2030. Glycopeptides are highly effective against severe gram-positive bacterial infections, which are major causes of sepsis. Their ability to inhibit cell wall synthesis in pathogens provides a strong therapeutic advantage, leading to increased adoption in hospital and ICU protocols.
The parenteral segment is expected to hold the largest share of the market over the forecast period. Parenteral administration ensures immediate bioavailability, which is vital in life-threatening conditions like sepsis, where time is critical. Intravenous drugs act faster than oral formulations, allowing clinicians to stabilize patients quickly and reduce mortality risks, thus supporting high adoption rates.
The oral segment is anticipated to be the fastest-growing segment in the market from 2025 to 2030. Oral sepsis therapeutics offer a cost-effective alternative to parenteral drugs, especially in low- and middle-income countries where hospital access is limited. Their affordability and ease of administration are contributing to higher adoption and market expansion in emerging regions.
The hospital pharmacies segment is expected to hold the largest share of the market over the forecast period. Hospital pharmacies are tightly integrated with emergency and intensive care units, where rapid therapeutic response is vital. Their proximity and round-the-clock operations make them indispensable in meeting the time-sensitive demands of sepsis treatment, securing their dominant market share.
The online pharmacies segment is anticipated to be the fastest-growing segment in the market from 2025 to 2030. When compared to regular pharmacies, online pharmacies can have reduced costs and special offers on sepsis medications. Cost-conscious consumers are drawn to this pricing advantage, especially in nations with high out-of-pocket medical costs, which fuels the segment's explosive growth.
North America is expected to be the largest region in the global market. North American hospitals rigorously follow sepsis management guidelines, including early detection and protocolized treatment. These practices lead to rapid administration of therapeutics, increasing consumption rates, and solidifying the region’s status as a leading market for sepsis-related drugs.
Asia Pacific is anticipated to witness rapid growth during the forecast period. Countries across the region are investing heavily in healthcare infrastructure development, including hospitals, ICUs, and diagnostic labs. This modernization is improving access to timely sepsis diagnosis and treatment, significantly contributing to the market's growth in the region.
Pfizer, Inc., GSK plc., AstraZeneca plc, Eli Lilly and Company, Astellas Pharma Inc., Bayer AG, InflaRx GmbH, La Jolla Pharmaceutical Co., T2 Biosystems Inc., and Aridis Pharmaceuticals Inc., among others, are some of the key players in the global sepsis therapeutics market.
Please note: This is not an exhaustive list of companies profiled in the report.
In September 2024, to strengthen the CDC's efforts on sepsis care, U.S. Senators Susan Collins, Chuck Schumer, and Bob Casey introduced the SEPSIS Act. The bill suggests a sepsis outcome measure, enhanced pediatric sepsis data collecting, cooperation with CMS and HHS on quality metrics, and an education campaign. A voluntary recognition program for hospitals with successful or developing sepsis strategies is also included.
In August 2023, Cytovale, a medical diagnostic company, commercialized the IntelliSep sepsis test, a new diagnostic tool, in the United States. For adult patients exhibiting symptoms and indications of infection, the test enables prompt identification of sepsis.
REPORT CONTENT
1 STRATEGIC INSIGHTS ON NEW REVENUE POCKETS
1.1 Strategic Opportunity & Attractiveness Analysis
1.1.1 Hot Revenue Pockets
1.1.2 Market Attractiveness Score
1.1.3 Revenue Impacting Opportunity
1.1.4 High Growing Region/Country
1.1.5 Competitor Analysis
1.1.6 Consumer Analysis
1.2 Global Market Estimates' View
1.3 Strategic Insights across Business Functions
1.3.1 For Chief Executive Officers
1.3.2 For Chief Marketing Officers
1.3.3 For Chief Strategy Officers
1.4 Evaluate the Potential of your Existing Business Lines vs. New Lines to Enter Into
2 TECHNOLOGICAL TRENDS
2.1 Technological Adoption Rate
2.2 Current Trend Impact Analysis
2.3 Future Trend Impact Analysis
3 GLOBAL SEPSIS THERAPEUTICS MARKET OUTLOOK
3.1 Market Pyramid Analysis
3.1.1 Introduction
3.1.2 Adjacent Market Opportunities
3.1.3 Ancillary Market Opportunities
3.2 Demand Side Analysis
3.2.1 Market Drivers: Impact Analysis
3.2.2 Market Restraints: Impact Analysis
3.2.3 Market Opportunities: Impact Analysis
3.2.4 Market Challenges: Impact Analysis
3.3 Supply Side Analysis
3.3.1 Porter’s Five Forces Analysis
3.3.1.1 Threat of New Entrants
3.3.1.2 Threat of New Substitutes
3.3.1.3 Bargaining Power of Suppliers
3.3.1.4 Bargaining Power of Buyers
3.3.1.5 Intensity of Competitive Rivalry
3.3.2 SWOT Analysis; By Factor (Political & Legal, Economic, and Technological)
3.3.2.1 Political Landscape
3.3.2.2 Economic Landscape
3.3.2.3 Social Landscape
3.3.2.4 Technology Landscape
3.3.3 Value Chain Analysis
3.3.4 Trend Analysis
3.3.5 Gap Analysis
3.3.6 Cost Analysis
4 GLOBAL SEPSIS THERAPEUTICS MARKET, BY DRUG CLASS
4.1 Introduction
4.2 Sepsis Therapeutics Market: Type Scope Key Takeaways
4.3 Revenue Growth Analysis, 2023 & 2029
4.4 Cephalosporin
4.4.1 Cephalosporin Market Estimates and Forecast, 2021-2029 (USD Million)
4.5 Aminoglycosides
4.5.1 Aminoglycosides Market Estimates and Forecast, 2021-2029 (USD Million)
4.6 Glycopeptide
4.6.1 Glycopeptide Market Estimates and Forecast, 2021-2029 (USD Million)
4.7 Others
4.7.1 Others Market Estimates and Forecast, 2021-2029 (USD Million)
5 GLOBAL SEPSIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION
5.1 Introduction
5.2 Sepsis Therapeutics Market: Route of Administration Scope Key Takeaways
5.3 Revenue Growth Analysis, 2023 & 2029
5.4 Parenteral
5.4.1 Parenteral Market Estimates and Forecast, 2021-2029 (USD Million)
5.5 Oral
5.5.1 Oral Market Estimates and Forecast, 2021-2029 (USD Million)
5.6 Others
5.6.1 Others Market Estimates and Forecast, 2021-2029 (USD Million)
6 GLOBAL SEPSIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL
6.1 Introduction
6.2 Sepsis Therapeutics Market: Distribution Channel Scope Key Takeaways
6.3 Revenue Growth Analysis, 2023 & 2029
6.4 Hospital Pharmacies
6.4.1 Hospital Pharmacies Market Estimates and Forecast, 2021-2029 (USD Million)
6.5 Retail Pharmacies
6.5.1 Retail Pharmacies Market Estimates and Forecast, 2021-2029 (USD Million)
6.6 Online Pharmacies
6.6.1 Online Pharmacies Market Estimates and Forecast, 2021-2029 (USD Million)
7 GLOBAL SEPSIS THERAPEUTICS MARKET, BY REGION
7.1 Introduction
7.2 North America Sepsis Therapeutics Market Estimates and Forecast, 2021-2029 (USD Million)
7.2.1 By Drug Class
7.2.2 By Route of Administration
7.2.3 By Distribution Channel
7.2.4 By Country
7.2.4.1 U.S. Sepsis Therapeutics Market Estimates and Forecast, 2021-2029 (USD Million)
7.2.4.1.1 By Drug Class
7.2.4.1.2 By Route of Administration
7.2.4.1.3 By Distribution Channel
7.2.4.2 Canada Sepsis Therapeutics Market Estimates and Forecast, 2021-2029 (USD Million)
7.2.4.2.1 By Drug Class
7.2.4.2.2 By Route of Administration
7.2.4.2.3 By Distribution Channel
7.2.4.3 Mexico Sepsis Therapeutics Market Estimates and Forecast, 2021-2029 (USD Million)
7.2.4.3.1 By Drug Class
7.2.4.3.2 By Route of Administration
7.2.4.3.3 By Distribution Channel
7.3 Europe Sepsis Therapeutics Market Estimates and Forecast, 2021-2029 (USD Million)
7.3.1 By Drug Class
7.3.2 By Route of Administration
7.3.3 By Distribution Channel
7.3.4 By Country
7.3.4.1 Germany Sepsis Therapeutics Market Estimates and Forecast, 2021-2029 (USD Million)
7.3.4.1.1 By Drug Class
7.3.4.1.2 By Route of Administration
7.3.4.1.3 By Distribution Channel
7.3.4.2 U.K. Sepsis Therapeutics Market Estimates and Forecast, 2021-2029 (USD Million)
7.3.4.2.1 By Drug Class
7.3.4.2.2 By Route of Administration
7.3.4.2.3 By Distribution Channel
7.3.4.3 France Sepsis Therapeutics Market Estimates and Forecast, 2021-2029 (USD Million)
7.3.4.3.1 By Drug Class
7.3.4.3.2 By Route of Administration
7.3.4.3.3 By Distribution Channel
7.3.4.4 Italy Sepsis Therapeutics Market Estimates and Forecast, 2021-2029 (USD Million)
7.3.4.4.1 By Drug Class
7.3.4.4.2 By Route of Administration
7.2.4.4.3 By Distribution Channel
7.3.4.5 Spain Sepsis Therapeutics Market Estimates and Forecast, 2021-2029 (USD Million)
7.3.4.5.1 By Drug Class
7.3.4.5.2 By Route of Administration
7.2.4.5.3 By Distribution Channel
7.3.4.6 Netherlands Sepsis Therapeutics Market Estimates and Forecast, 2021-2029 (USD Million)
7.3.4.6.1 By Drug Class
7.3.4.6.2 By Route of Administration
7.2.4.6.3 By Distribution Channel
7.3.4.7 Rest of Europe Sepsis Therapeutics Market Estimates and Forecast, 2021-2029 (USD Million)
7.3.4.7.1 By Drug Class
7.3.4.7.2 By Route of Administration
7.2.4.7.3 By Distribution Channel
7.4 Asia Pacific Sepsis Therapeutics Market Estimates and Forecast, 2021-2029 (USD Million)
7.4.1 By Drug Class
7.4.2 By Route of Administration
7.4.3 By Distribution Channel
7.4.4 By Country
7.4.4.1 China Sepsis Therapeutics Market Estimates and Forecast, 2021-2029 (USD Million)
7.4.4.1.1 By Drug Class
7.4.4.1.2 By Route of Administration
7.4.4.1.3 By Distribution Channel
7.4.4.2 Japan Sepsis Therapeutics Market Estimates and Forecast, 2021-2029 (USD Million)
7.4.4.2.1 By Drug Class
7.4.4.2.2 By Route of Administration
7.4.4.2.3 By Distribution Channel
7.4.4.3 India Sepsis Therapeutics Market Estimates and Forecast, 2021-2029 (USD Million)
7.4.4.3.1 By Drug Class
7.4.4.3.2 By Route of Administration
7.4.4.3.3 By Distribution Channel
7.4.4.4 South Korea Sepsis Therapeutics Market Estimates and Forecast, 2021-2029 (USD Million)
7.4.4.4.1 By Drug Class
7.4.4.4.2 By Route of Administration
7.4.4.4.3 By Distribution Channel
7.4.4.5 Singapore Sepsis Therapeutics Market Estimates and Forecast, 2021-2029 (USD Million)
7.4.4.5.1 By Drug Class
7.4.4.5.2 By Route of Administration
7.4.4.5.3 By Distribution Channel
7.4.4.6 Malaysia Sepsis Therapeutics Market Estimates and Forecast, 2021-2029 (USD Million)
7.4.4.6.1 By Drug Class
7.4.4.6.2 By Route of Administration
7.4.4.6.3 By Distribution Channel
7.4.4.7 Thailand Sepsis Therapeutics Market Estimates and Forecast, 2021-2029 (USD Million)
7.4.4.7.1 By Drug Class
7.4.4.7.2 By Route of Administration
7.4.4.7.3 By Distribution Channel
7.4.4.8 Indonesia Sepsis Therapeutics Market Estimates and Forecast, 2021-2029 (USD Million)
7.4.4.8.1 By Drug Class
7.4.4.8.2 By Route of Administration
7.4.4.8.3 By Distribution Channel
7.4.4.9 Vietnam Sepsis Therapeutics Market Estimates and Forecast, 2021-2029 (USD Million)
7.4.4.9.1 By Drug Class
7.4.4.9.2 By Route of Administration
7.4.4.9.3 By Distribution Channel
7.4.4.10 Taiwan Sepsis Therapeutics Market Estimates and Forecast, 2021-2029 (USD Million)
7.4.4.10.1 By Drug Class
7.4.4.10.2 By Route of Administration
7.4.4.10.3 By Distribution Channel
7.4.4.11 Rest of Asia Pacific Sepsis Therapeutics Market Estimates and Forecast, 2021-2029 (USD Million)
7.4.4.11.1 By Drug Class
7.4.4.11.2 By Route of Administration
7.4.4.11.3 By Distribution Channel
7.5 Middle East and Africa Sepsis Therapeutics Market Estimates and Forecast, 2021-2029 (USD Million)
7.5.1 By Drug Class
7.5.2 By Route of Administration
7.5.3 By Distribution Channel
7.5.4 By Country
7.5.4.1 Saudi Arabia Sepsis Therapeutics Market Estimates and Forecast, 2021-2029 (USD Million)
7.5.4.1.1 By Drug Class
7.5.4.1.2 By Route of Administration
7.5.4.1.3 By Distribution Channel
7.5.4.2 U.A.E. Sepsis Therapeutics Market Estimates and Forecast, 2021-2029 (USD Million)
7.5.4.2.1 By Drug Class
7.5.4.2.2 By Route of Administration
7.5.4.2.3 By Distribution Channel
7.5.4.3 Israel Sepsis Therapeutics Market Estimates and Forecast, 2021-2029 (USD Million)
7.5.4.3.1 By Drug Class
7.5.4.3.2 By Route of Administration
7.5.4.3.3 By Distribution Channel
7.5.4.4 South Africa Sepsis Therapeutics Market Estimates and Forecast, 2021-2029 (USD Million)
7.5.4.4.1 By Drug Class
7.5.4.4.2 By Route of Administration
7.5.4.4.3 By Distribution Channel
7.5.4.5 Rest of Middle East and Africa Sepsis Therapeutics Market Estimates and Forecast, 2021-2029 (USD Million)
7.5.4.5.1 By Drug Class
7.5.4.5.2 By Route of Administration
7.5.4.5.2 By Distribution Channel
7.6 Central and South America Sepsis Therapeutics Market Estimates and Forecast, 2021-2029 (USD Million)
7.6.1 By Drug Class
7.6.2 By Route of Administration
7.6.3 By Distribution Channel
7.6.4 By Country
7.6.4.1 Brazil Sepsis Therapeutics Market Estimates and Forecast, 2021-2029 (USD Million)
7.6.4.1.1 By Drug Class
7.6.4.1.2 By Route of Administration
7.6.4.1.3 By Distribution Channel
7.6.4.2 Argentina Sepsis Therapeutics Market Estimates and Forecast, 2021-2029 (USD Million)
7.6.4.2.1 By Drug Class
7.6.4.2.2 By Route of Administration
7.6.4.2.3 By Distribution Channel
7.6.4.3 Chile Sepsis Therapeutics Market Estimates and Forecast, 2021-2029 (USD Million)
7.6.4.3.1 By Drug Class
7.6.4.3.2 By Route of Administration
7.6.4.3.3 By Distribution Channel
7.6.4.4 Rest of Central and South America Sepsis Therapeutics Market Estimates and Forecast, 2021-2029 (USD Million)
7.6.4.4.1 By Drug Class
7.6.4.4.2 By Route of Administration
7.6.4.4.3 By Distribution Channel
8 COMPETITIVE LANDCAPE
8.1 Company Market Share Analysis
8.2 Four Quadrant Positioning Matrix
8.2.1 Market Leaders
8.2.2 Market Visionaries
8.2.3 Market Challengers
8.2.4 Niche Market Players
8.3 Vendor Landscape
8.3.1 North America
8.3.2 Europe
8.3.3 Asia Pacific
8.3.4 Rest of the World
8.4 Company Profiles
8.4.1 Pfizer, Inc.
8.4.1.1 Business Description & Financial Analysis
8.4.1.2 SWOT Analysis
8.4.1.3 Products & Services Offered
8.4.1.4 Strategic Alliances between Business Partners
8.4.2 GSK plc.
8.4.2.1 Business Description & Financial Analysis
8.4.2.2 SWOT Analysis
8.4.2.3 Products & Services Offered
8.4.2.4 Strategic Alliances between Business Partners
8.4.3 AstraZeneca plc
8.4.3.1 Business Description & Financial Analysis
8.4.3.2 SWOT Analysis
8.4.3.3 Products & Services Offered
8.4.3.4 Strategic Alliances between Business Partners
8.4.4 Eli Lilly and Company
8.4.4.1 Business Description & Financial Analysis
8.4.4.2 SWOT Analysis
8.4.4.3 Products & Services Offered
8.4.4.4 Strategic Alliances between Business Partners
8.4.5 Astellas Pharma Inc.
8.4.5.1 Business Description & Financial Analysis
8.4.5.2 SWOT Analysis
8.4.5.3 Products & Services Offered
8.4.5.4 Strategic Alliances between Business Partners
8.4.6 BAYER AG
8.4.6.1 Business Description & Financial Analysis
8.4.6.2 SWOT Analysis
8.4.6.3 Products & Services Offered
8.4.6.4 Strategic Alliances between Business Partners
8.4.7 InflaRx GmbH
8.4.7.1 Business Description & Financial Analysis
8.4.7.2 SWOT Analysis
8.4.7.3 Products & Services Offered
8.4.8.4 Strategic Alliances between Business Partners
8.4.8 La Jolla Pharmaceutical Co.
8.4.8.1 Business Description & Financial Analysis
8.4.8.2 SWOT Analysis
8.4.8.3 Products & Services Offered
8.4.8.4 Strategic Alliances between Business Partners
8.4.9 T2 Biosystems Inc.
8.4.9.1 Business Description & Financial Analysis
8.4.9.2 SWOT Analysis
8.4.9.3 Products & Services Offered
8.4.9.4 Strategic Alliances between Business Partners
8.4.10 Aridis Pharmaceuticals Inc.
8.4.10.1 Business Description & Financial Analysis
8.4.10.2 SWOT Analysis
8.4.10.3 Products & Services Offered
8.4.10.4 Strategic Alliances between Business Partners
8.4.11 Other Companies
8.4.11.1 Business Description & Financial Analysis
8.4.11.2 SWOT Analysis
8.4.11.3 Products & Services Offered
8.4.11.4 Strategic Alliances between Business Partners
9 RESEARCH METHODOLOGY
9.1 Market Introduction
9.1.1 Market Definition
9.1.2 Market Scope & Segmentation
9.2 Information Procurement
9.2.1 Secondary Research
9.2.1.1 Purchased Databases
9.2.1.2 GMEs Internal Data Repository
9.2.1.3 Secondary Resources & Third Party Perspectives
9.2.1.4 Company Information Sources
9.2.2 Primary Research
9.2.2.1 Various Types of Respondents for Primary Interviews
9.2.2.2 Number of Interviews Conducted throughout the Research Process
9.2.2.3 Primary Stakeholders
9.2.2.4 Discussion Guide for Primary Participants
9.2.3 Expert Panels
9.2.3.1 Expert Panels Across 30+ Industry
9.2.4 Paid Local Experts
9.2.4.1 Paid Local Experts Across 30+ Industry Across each Region
9.3 Market Estimation
9.3.1 Top-Down Approach
9.3.1.1 Macro-Economic Indicators Considered
9.3.1.2 Micro-Economic Indicators Considered
9.3.2 Bottom Up Approach
9.3.2.1 Company Share Analysis Approach
9.3.2.2 Estimation of Potential Type Sales
9.4 Data Triangulation
9.4.1 Data Collection
9.4.2 Time Series, Cross Sectional & Panel Data Analysis
9.4.3 Cluster Analysis
9.5 Analysis and Output
9.5.1 Inhouse AI Based Real Time Analytics Tool
9.5.2 Output From Desk & Primary Research
9.6 Research Assumptions & Limitations
9.7.1 Research Assumptions
9.7.2 Research Limitations
LIST OF TABLES
1 Global Sepsis Therapeutics Market, By Drug Class, 2021-2029 (USD Million)
2 Cephalosporin Market, By Region, 2021-2029 (USD Million)
3 Aminoglycosides Market, By Region, 2021-2029 (USD Million)
4 Glycopeptide Market, By Region, 2021-2029 (USD Million)
5 Others Market, By Region, 2021-2029 (USD Million)
6 Global Sepsis Therapeutics Market, By Route of Administration, 2021-2029 (USD Million)
7 Parenteral Market, By Region, 2021-2029 (USD Million)
8 Oral Market, By Region, 2021-2029 (USD Million)
9 Others Market, By Region, 2021-2029 (USD Million)
10 Global Sepsis Therapeutics Market, By Distribution Channel, 2021-2029 (USD Million)
11 Hospital Pharmacies Market, By Region, 2021-2029 (USD Million)
12 Retail Pharmacies Market, By Region, 2021-2029 (USD Million)
13 Online Pharmacies Market, By Region, 2021-2029 (USD Million)
14 Regional Analysis, 2021-2029 (USD Million)
15 North America Sepsis Therapeutics Market, By Drug Class, 2021-2029 (USD Million)
16 North America Sepsis Therapeutics Market, By Route of Administration, 2021-2029 (USD Million)
17 North America Sepsis Therapeutics Market, By Distribution Channel, 2021-2029 (USD Million)
18 North America Sepsis Therapeutics Market, By Country, 2021-2029 (USD Million)
19 U.S Sepsis Therapeutics Market, By Drug Class, 2021-2029 (USD Million)
20 U.S Sepsis Therapeutics Market, By Route of Administration, 2021-2029 (USD Million)
21 U.S Sepsis Therapeutics Market, By Distribution Channel, 2021-2029 (USD Million)
22 Canada Sepsis Therapeutics Market, By Drug Class, 2021-2029 (USD Million)
23 Canada Sepsis Therapeutics Market, By Route of Administration, 2021-2029 (USD Million)
24 Canada Sepsis Therapeutics Market, By Distribution Channel, 2021-2029 (USD Million)
25 Mexico Sepsis Therapeutics Market, By Drug Class, 2021-2029 (USD Million)
26 Mexico Sepsis Therapeutics Market, By Route of Administration, 2021-2029 (USD Million)
27 Mexico Sepsis Therapeutics Market, By Distribution Channel, 2021-2029 (USD Million)
28 Europe Sepsis Therapeutics Market, By Drug Class, 2021-2029 (USD Million)
29 Europe Sepsis Therapeutics Market, By Route of Administration, 2021-2029 (USD Million)
30 Europe Sepsis Therapeutics Market, By Distribution Channel, 2021-2029 (USD Million)
31 Europe Sepsis Therapeutics Market, By Country 2021-2029 (USD Million)
32 Germany Sepsis Therapeutics Market, By Drug Class, 2021-2029 (USD Million)
33 Germany Sepsis Therapeutics Market, By Route of Administration, 2021-2029 (USD Million)
34 Germany Sepsis Therapeutics Market, By Distribution Channel, 2021-2029 (USD Million)
35 U.K Sepsis Therapeutics Market, By Drug Class, 2021-2029 (USD Million)
36 U.K Sepsis Therapeutics Market, By Route of Administration, 2021-2029 (USD Million)
37 U.K Sepsis Therapeutics Market, By Distribution Channel, 2021-2029 (USD Million)
38 France Sepsis Therapeutics Market, By Drug Class, 2021-2029 (USD Million)
39 France Sepsis Therapeutics Market, By Route of Administration, 2021-2029 (USD Million)
40 France Sepsis Therapeutics Market, By Distribution Channel, 2021-2029 (USD Million)
41 Italy Sepsis Therapeutics Market, By Drug Class, 2021-2029 (USD Million)
42 Italy Sepsis Therapeutics Market, By Route of Administration, 2021-2029 (USD Million)
43 Italy Sepsis Therapeutics Market, By Distribution Channel, 2021-2029 (USD Million)
44 Spain Sepsis Therapeutics Market, By Drug Class, 2021-2029 (USD Million)
45 Spain Sepsis Therapeutics Market, By Route of Administration, 2021-2029 (USD Million)
46 Spain Sepsis Therapeutics Market, By Distribution Channel, 2021-2029 (USD Million)
47 Netherlands Sepsis Therapeutics Market, By Drug Class, 2021-2029 (USD Million)
48 Netherlands Sepsis Therapeutics Market, By Route of Administration, 2021-2029 (USD Million)
49 Netherlands Sepsis Therapeutics Market, By Distribution Channel, 2021-2029 (USD Million)
50 Rest Of Europe Sepsis Therapeutics Market, By Drug Class, 2021-2029 (USD Million)
51 Rest Of Europe Sepsis Therapeutics Market, By Route of Administration, 2021-2029 (USD Million)
52 Rest of Europe Sepsis Therapeutics Market, By Distribution Channel, 2021-2029 (USD Million)
53 Asia Pacific Sepsis Therapeutics Market, By Drug Class, 2021-2029 (USD Million)
54 Asia Pacific Sepsis Therapeutics Market, By Route of Administration, 2021-2029 (USD Million)
55 Asia Pacific Sepsis Therapeutics Market, By Distribution Channel, 2021-2029 (USD Million)
56 Asia Pacific Sepsis Therapeutics Market, By Country, 2021-2029 (USD Million)
57 China Sepsis Therapeutics Market, By Drug Class, 2021-2029 (USD Million)
58 China Sepsis Therapeutics Market, By Route of Administration, 2021-2029 (USD Million)
59 China Sepsis Therapeutics Market, By Distribution Channel, 2021-2029 (USD Million)
60 India Sepsis Therapeutics Market, By Drug Class, 2021-2029 (USD Million)
61 India Sepsis Therapeutics Market, By Route of Administration, 2021-2029 (USD Million)
62 India Sepsis Therapeutics Market, By Distribution Channel, 2021-2029 (USD Million)
63 Japan Sepsis Therapeutics Market, By Drug Class, 2021-2029 (USD Million)
64 Japan Sepsis Therapeutics Market, By Route of Administration, 2021-2029 (USD Million)
65 Japan Sepsis Therapeutics Market, By Distribution Channel, 2021-2029 (USD Million)
66 South Korea Sepsis Therapeutics Market, By Drug Class, 2021-2029 (USD Million)
67 South Korea Sepsis Therapeutics Market, By Route of Administration, 2021-2029 (USD Million)
68 South Korea Sepsis Therapeutics Market, By Distribution Channel, 2021-2029 (USD Million)
69 malaysia Sepsis Therapeutics Market, By Drug Class, 2021-2029 (USD Million)
70 malaysia Sepsis Therapeutics Market, By Route of Administration, 2021-2029 (USD Million)
71 malaysia Sepsis Therapeutics Market, By Distribution Channel, 2021-2029 (USD Million)
72 Thailand Sepsis Therapeutics Market, By Drug Class, 2021-2029 (USD Million)
73 Thailand Sepsis Therapeutics Market, By Route of Administration, 2021-2029 (USD Million)
74 Thailand Sepsis Therapeutics Market, By Distribution Channel, 2021-2029 (USD Million)
75 Indonesia Sepsis Therapeutics Market, By Drug Class, 2021-2029 (USD Million)
76 Indonesia Sepsis Therapeutics Market, By Route of Administration, 2021-2029 (USD Million)
77 Indonesia Sepsis Therapeutics Market, By Distribution Channel, 2021-2029 (USD Million)
78 Vietnam Sepsis Therapeutics Market, By Drug Class, 2021-2029 (USD Million)
79 Vietnam Sepsis Therapeutics Market, By Route of Administration, 2021-2029 (USD Million)
80 Vietnam Sepsis Therapeutics Market, By Distribution Channel, 2021-2029 (USD Million)
81 Taiwan Sepsis Therapeutics Market, By Drug Class, 2021-2029 (USD Million)
82 Taiwan Sepsis Therapeutics Market, By Route of Administration, 2021-2029 (USD Million)
83 Taiwan Sepsis Therapeutics Market, By Distribution Channel, 2021-2029 (USD Million)
84 Rest of Asia Pacific Sepsis Therapeutics Market, By Drug Class, 2021-2029 (USD Million)
85 Rest of Asia Pacific Sepsis Therapeutics Market, By Route of Administration, 2021-2029 (USD Million)
86 Rest of Asia Pacific Sepsis Therapeutics Market, By Distribution Channel, 2021-2029 (USD Million)
87 Middle East and Africa Sepsis Therapeutics Market, By Drug Class, 2021-2029 (USD Million)
88 Middle East and Africa Sepsis Therapeutics Market, By Route of Administration, 2021-2029 (USD Million)
89 Middle East and Africa Sepsis Therapeutics Market, By Distribution Channel, 2021-2029 (USD Million)
90 Middle East and Africa Sepsis Therapeutics Market, By Country, 2021-2029 (USD Million)
91 Saudi Arabia Sepsis Therapeutics Market, By Drug Class, 2021-2029 (USD Million)
92 Saudi Arabia Sepsis Therapeutics Market, By Route of Administration, 2021-2029 (USD Million)
93 Saudi Arabia Sepsis Therapeutics Market, By Distribution Channel, 2021-2029 (USD Million)
94 UAE Sepsis Therapeutics Market, By Drug Class, 2021-2029 (USD Million)
95 UAE Sepsis Therapeutics Market, By Route of Administration, 2021-2029 (USD Million)
96 UAE Sepsis Therapeutics Market, By Distribution Channel, 2021-2029 (USD Million)
97 Israel Sepsis Therapeutics Market, By Drug Class, 2021-2029 (USD Million)
98 Israel Sepsis Therapeutics Market, By Route of Administration, 2021-2029 (USD Million)
99 Israel Sepsis Therapeutics Market, By Distribution Channel, 2021-2029 (USD Million)
100 South Africa Sepsis Therapeutics Market, By Drug Class, 2021-2029 (USD Million)
101 South Africa Sepsis Therapeutics Market, By Route of Administration, 2021-2029 (USD Million)
102 South Africa Sepsis Therapeutics Market, By Distribution Channel, 2021-2029 (USD Million)
103 Rest of Middle East and Africa Sepsis Therapeutics Market, By Drug Class, 2021-2029 (USD Million)
104 Rest of Middle East and Africa Sepsis Therapeutics Market, By Route of Administration, 2021-2029 (USD Million)
105 Rest of Middle East and Africa Sepsis Therapeutics Market, By Distribution Channel, 2021-2029 (USD Million)
106 Central and South America Sepsis Therapeutics Market, By Drug Class, 2021-2029 (USD Million)
107 Central and South America Sepsis Therapeutics Market, By Route of Administration, 2021-2029 (USD Million)
108 Central and South America Sepsis Therapeutics Market, By Distribution Channel, 2021-2029 (USD Million)
109 Central and South America Sepsis Therapeutics Market, By Country, 2021-2029 (USD Million)
110 Brazil Sepsis Therapeutics Market, By Drug Class, 2021-2029 (USD Million)
111 Brazil Sepsis Therapeutics Market, By Route of Administration, 2021-2029 (USD Million)
112 Brazil Sepsis Therapeutics Market, By Distribution Channel, 2021-2029 (USD Million)
113 Argentina Sepsis Therapeutics Market, By Drug Class, 2021-2029 (USD Million)
114 Argentina Sepsis Therapeutics Market, By Route of Administration, 2021-2029 (USD Million)
115 Argentina Sepsis Therapeutics Market, By Distribution Channel, 2021-2029 (USD Million)
116 Chile Sepsis Therapeutics Market, By Drug Class, 2021-2029 (USD Million)
117 Chile Sepsis Therapeutics Market, By Route of Administration, 2021-2029 (USD Million)
118 Chile Sepsis Therapeutics Market, By Distribution Channel, 2021-2029 (USD Million)
119 Rest of Central and South America Sepsis Therapeutics Market, By Drug Class, 2021-2029 (USD Million)
120 Rest of Central and South America Sepsis Therapeutics Market, By Route of Administration, 2021-2029 (USD Million)
121 Rest of Central and South America Sepsis Therapeutics Market, By Distribution Channel, 2021-2029 (USD Million)
122 Pfizer, Inc.: Products & Services Offering
123 GSK plc.: Products & Services Offering
124 AstraZeneca plc: Products & Services Offering
125 Eli Lilly and Company: Products & Services Offering
126 Astellas Pharma Inc.: Products & Services Offering
127 BAYER AG: Products & Services Offering
128 InflaRx GmbH: Products & Services Offering
129 La Jolla Pharmaceutical Co.: Products & Services Offering
130 T2 Biosystems Inc., Inc: Products & Services Offering
131 Aridis Pharmaceuticals Inc.: Products & Services Offering
132 Other Companies: Products & Services Offering
LIST OF FIGURES
1 Global Sepsis Therapeutics Market Overview
2 Global Sepsis Therapeutics Market Value From 2021-2029 (USD Million)
3 Global Sepsis Therapeutics Market Share, By Drug Class (2023)
4 Global Sepsis Therapeutics Market Share, By Route of Administration (2023)
5 Global Sepsis Therapeutics Market Share, By Distribution Channel (2023)
6 Global Sepsis Therapeutics Market, By Region (Asia Pacific Market)
7 Technological Trends In Global Sepsis Therapeutics Market
8 Four Quadrant Competitor Positioning Matrix
9 Impact Of Macro & Micro Indicators On The Market
10 Impact Of Key Drivers On The Global Sepsis Therapeutics Market
11 Impact Of Challenges On The Global Sepsis Therapeutics Market
12 Porter’s Five Forces Analysis
13 Global Sepsis Therapeutics Market: By Drug Class Scope Key Takeaways
14 Global Sepsis Therapeutics Market, By Drug Class Segment: Revenue Growth Analysis
15 Cephalosporin Market, By Region, 2021-2029 (USD Million)
16 Aminoglycosides Market, By Region, 2021-2029 (USD Million)
17 Glycopeptide Market, By Region, 2021-2029 (USD Million)
18 Others Market, By Region, 2021-2029 (USD Million)
19 Global Sepsis Therapeutics Market: By Route of Administration Scope Key Takeaways
20 Global Sepsis Therapeutics Market, By Route of Administration Segment: Revenue Growth Analysis
21 Parenteral Market, By Region, 2021-2029 (USD Million)
22 Oral Market, By Region, 2021-2029 (USD Million)
23 Others Market, By Region, 2021-2029 (USD Million)
24 Global Sepsis Therapeutics Market: By Distribution Channel Scope Key Takeaways
25 Global Sepsis Therapeutics Market, By Distribution Channel Segment: Revenue Growth Analysis
26 Hospital Pharmacies Market, By Region, 2021-2029 (USD Million)
27 Retail Pharmacies Market, By Region, 2021-2029 (USD Million)
28 Online Pharmacies Market, By Region, 2021-2029 (USD Million)
29 Regional Segment: Revenue Growth Analysis
30 Global Sepsis Therapeutics Market: Regional Analysis
31 North America Sepsis Therapeutics Market Overview
32 North America Sepsis Therapeutics Market, By Drug Class
33 North America Sepsis Therapeutics Market, By Route of Administration
34 North America Sepsis Therapeutics Market, By Distribution Channel
35 North America Sepsis Therapeutics Market, By Country
36 U.S. Sepsis Therapeutics Market, By Drug Class
37 U.S. Sepsis Therapeutics Market, By Route of Administration
38 U.S. Sepsis Therapeutics Market, By Distribution Channel
39 Canada Sepsis Therapeutics Market, By Drug Class
40 Canada Sepsis Therapeutics Market, By Route of Administration
41 Canada Sepsis Therapeutics Market, By Distribution Channel
42 Mexico Sepsis Therapeutics Market, By Drug Class
43 Mexico Sepsis Therapeutics Market, By Route of Administration
44 Mexico Sepsis Therapeutics Market, By Distribution Channel
45 Four Quadrant Positioning Matrix
46 Company Market Share Analysis
47 Pfizer, Inc.: Company Snapshot
48 Pfizer, Inc.: SWOT Analysis
49 Pfizer, Inc.: Geographic Presence
50 GSK plc.: Company Snapshot
51 GSK plc.: SWOT Analysis
52 GSK plc.: Geographic Presence
53 AstraZeneca plc: Company Snapshot
54 AstraZeneca plc: SWOT Analysis
55 AstraZeneca plc: Geographic Presence
56 Eli Lilly and Company: Company Snapshot
57 Eli Lilly and Company: Swot Analysis
58 Eli Lilly and Company: Geographic Presence
59 Astellas Pharma Inc.: Company Snapshot
60 Astellas Pharma Inc.: SWOT Analysis
61 Astellas Pharma Inc.: Geographic Presence
62 BAYER AG: Company Snapshot
63 BAYER AG: SWOT Analysis
64 BAYER AG: Geographic Presence
65 InflaRx GmbH : Company Snapshot
66 InflaRx GmbH : SWOT Analysis
67 InflaRx GmbH : Geographic Presence
68 La Jolla Pharmaceutical Co.: Company Snapshot
69 La Jolla Pharmaceutical Co.: SWOT Analysis
70 La Jolla Pharmaceutical Co.: Geographic Presence
71 T2 Biosystems Inc., Inc.: Company Snapshot
72 T2 Biosystems Inc., Inc.: SWOT Analysis
73 T2 Biosystems Inc., Inc.: Geographic Presence
74 Aridis Pharmaceuticals Inc.: Company Snapshot
75 Aridis Pharmaceuticals Inc.: SWOT Analysis
76 Aridis Pharmaceuticals Inc.: Geographic Presence
77 Other Companies: Company Snapshot
78 Other Companies: SWOT Analysis
79 Other Companies: Geographic Presence
The Global Sepsis Therapeutics Market has been studied from the year 2019 till 2030. However, the CAGR provided in the report is from the year 2025 to 2030. The research methodology involved three stages: Desk research, Primary research, and Analysis & Output from the entire research process.
The desk research involved a robust background study which meant referring to paid and unpaid databases to understand the market dynamics; mapping contracts from press releases; identifying the key players in the market, studying their product portfolio, competition level, annual reports/SEC filings & investor presentations; and learning the demand and supply-side analysis for the Sepsis Therapeutics Market.
The primary research activity included telephonic conversations with more than 50 tier 1 industry consultants, distributors, and end-use product manufacturers.
Finally, based on the above thorough research process, an in-depth analysis was carried out considering the following aspects: market attractiveness, current & future market trends, market share analysis, SWOT analysis of the company and customer analytics.
Frequently Asked Questions
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
Or view our licence options:
Tailor made solutions just for you
80% of our clients seek made-to-order reports. How do you want us to tailor yours?
OUR CLIENTS
